http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 19 Mar 2025 01:07:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Press+Releases/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html <p class="bwalignc"> —Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing — </p> <p> TOKYO--(BUSINESS WIRE)-- PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHC"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. (Headquarters: Minato-ku, Tokyo; CEO: Shizuka Akieda; hereafter referred to as "Cyfuse") announce the successful development of a new production technology(*1) for the commercialization of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. </p><p id="news-body-cta">This http://www.streetinsider.com/Business+Wire/PHC+and+Cyfuse+Develop+Innovative+Production+Technology+for+the+Commercialization+of+3D+Cell+Products/24519317.html Wed, 19 Mar 2025 01:07:00 -0500 6523 A.07070846 A.37075391 A.50203556 A.50213550 O.01196492 O.17033881 O.21454171 O.25443386 O.35229939 PHC http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html si-local-file:///var/storage/newsbody/2023/0403/21461131.html http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html Mon, 03 Apr 2023 22:00:00 -0500 A.07070846 A.17568957 A.37075391 A.60012013 O.01196492 O.04889877 O.25443386 PHC http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html si-local-file:///var/storage/newsbody/2023/0403/21461131.html http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html Mon, 03 Apr 2023 22:00:00 -0500 A.07070846 A.17568957 A.37075391 A.60012013 O.01196492 O.04889877 O.25443386 PHC http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html si-local-file:///var/storage/newsbody/2023/0403/21461131.html http://www.streetinsider.com/Press+Releases/PHC+Corporation+and+NovaScan%2C+Inc.+Launch+Collaboration+to+Explore+the+Feasibility+of+a+Device+that+Supports+Non-melanoma+Skin+Cancer+Detection/21461131.html Mon, 03 Apr 2023 22:00:00 -0500 A.07070846 A.17568957 A.37075391 A.60012013 O.01196492 O.04889877 O.25443386 PHC